Nurix Therapeutics(NRIX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O'Connor, M.D., as chief medical of icer and Pasit Phiasivongsa, Ph.D., as chief technical of icer Strengthened financial position ending the quarter with cash and mar ...